1. PERSONAL DETAILS
8 Cody Ave
Baltimore, MD 21234
Department of Resesarch
Schapiro Building, Suite 317
2401 West Belvedere Ave
Baltimore, MD 21215
ayabut@lifebridgehealth.org
(410) 601-5559
CERTIFICATIONS
CITI Program
Basic Biomedical Research
Good Clinical Practice
Alexander Yabut
Research Coordinator
EMPLOYMENT HISTORY
January 2015 - Present
Administrative Research Coordinator
Sinai Hospital of Baltimore
LifeBridge Health, Inc.
Baltimore, Maryland
Department of Research – Research Coordinator Program
Administrative Research Coordinator
Northwest Hospital Center
LifeBridge Health, Inc.
Randallstown, Maryland
Department of Research – Research Coordinator Program
ACADEMIC HISTORY
New York University
Bachelor of Arts
Economic Policy
2008 – 2012
PROFESSIONAL RESEARCH EXPERIENCE
ResearchCoordinator:
 An ACromegaly, open-label, multi-CEnter, Safety monitoring program for treating patients
with SOM230 (pasireotide) LAR who have need to receive medical therapy (ACCESS)
 The Answer Program: American Norditropin Studies: Web Enabled Research. Norditropin
National Registry
 Community Access to Child Health (CATCH): Building Bridges to Adult Medical Homes
 Cardiovascular Inflammation Reduction Trial (CIRT): A randomized, double-blind, placebo-
controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of

2. cardiovascular events among stable coronary artery disease patients with type 2 diabetes or
metabolic syndrome
 A Randomized, Double-Blind, Event Driven, Multicenter, Study Comparing the Efficacy and
Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death, Myocardial
Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery
Disease Following a Hospitalization for Exacerbation of Heart Failure
 Non-interventional study for the generation of long term safety and efficacy data of
pasireotide s.c. in patients with Cushing’s disease (Post-Authorization Safety Study)
(CSOM230B2410)
 CRT Implant Strategy Using the Longest Electrial Delay for Non-left Bundle Branch Block
Patients (ENHANCE CRT)
 EXenatide Study of Cardiovascular Event Lowering Trial (EXSCEL)
 The Inciednce of Vitamin D Deficiency in Children with T1DM in Northeast Ohio
 Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-
Discharge Venous Thrombo-Embolism Risk (MARINER)
 A Phase III, Multicenter, Double-Blind, Randomized, Placebo-and Metformin-Controlled
Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with
Type 2 Diabetes Mellitus with Inadequate Glycemic Control
 Pilot Study: Resting Membrane Potential of White Blood Cells as an indicator for
Defibrillator Shock
 Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II - ORBIT-AF II
 PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A
Natural History Registry for Patients with Chronic Hypoparathyroidism K
 Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients
with MS newly started on fingolimod once daily or treated with another approved disease-
modifying therapy
 A Phase IIIb, Double-Blind, Multicenter Study To Evaluate The Efficacy And Safety Of
Alteplase In Patients With Mild Stroke: Rapidly Improving Symptoms And Minor
Neurologic Deficits (Prisms)
 A Phase III, case series clinical study of the reversal of the anticoagulant effects of
dabigatran by intravenous administration of 5.0 g idarucizumb (BI 655075) in patients
treated with dabigatran etexilate who have uncontrolled bleeding or require emergency
surgery or procedures. RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab
on Active Dabigatran) trial